CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trial Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk Impact of Staging Percutaneous Coronary Intervention in Left Main Artery Disease: Insights From the EXCEL Trial Ticagrelor With or Without Aspirin After Complex PCI A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling Dual Antiplatelet TherapyIs It Time to Cut the Cord With Aspirin? Does Risk of Premature Discontinuation of Dual-Antiplatelet Therapy Following PCI Attenuate With Increasing Age? Impact of SYNTAX Score on 10-Year Outcomes After Revascularization for Left Main Coronary Artery Disease Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR Stress Echocardiography and PH: What Do the Findings Mean?
|<<... 124 125 126 127 128 129 130 ...>>|

Clinical Trial2016 Jan 21;37(4):365-74.

JOURNAL：Eur Heart J. Article Link

Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial

Helft G, Steg PG, OPTImal DUAL Antiplatelet Therapy Trial Investigators. Keywords: DAPT duration; coronary artery disease; DES; platelet aggregation; inhibitors; stents; thrombosis

ABSTRACT

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top